Indivior and Supernus announce merger of equals to create diversified CNS leader

Indivior Pharmaceuticals, Inc.

Merger of equals under Agreement and Plan of Merger dated August 1, 2026.
Joint investor presentation and conference call held on August 3, 2026.
Transaction includes a special dividend and additional indebtedness; terms not disclosed.
Closing subject to stockholder and regulatory approvals; S-4 registration statement to be filed.
Combined company expected to have significant scale in CNS biopharmaceuticals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.